BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11165130)

  • 21. Combined treatment with chemotherapy and neutron irradiation for limited non-small-cell lung cancer: a Southwest Oncology Group Study.
    Livingston RB; Griffin BR; Higano CS; Laramore GE; Rivkin SE; Goldberg RS; Schulman SF
    J Clin Oncol; 1987 Nov; 5(11):1716-24. PubMed ID: 2824705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.
    Kubota K; Furuse K; Kawahara M; Kodama N; Yamamoto M; Ogawara M; Negoro S; Masuda N; Takada M; Matsui K
    J Clin Oncol; 1994 Aug; 12(8):1547-52. PubMed ID: 8040666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical investigation of weekly cisplatin and vinorelbine with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Furihata T; Ishii Y; Miyoshi M; Fukushima F; Hayashi Y; Arai R; Kamiya C; Tatewaki M; Fukushima Y; Fukuda T
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1313-6. PubMed ID: 21829070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
    Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
    Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy.
    Trinh H; Pinkham MB; Lehman M; Zarate D; Dauth M; McGrath M; McCaffrey E; Mai GT; Horwood K
    Clin Respir J; 2016 Jul; 10(4):428-34. PubMed ID: 25353367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lung toxicity of trimodality chemoradiotherapy with mitomycin C, vindesine, and cisplatin followed by surgery for locally advanced non-small cell lung cancer].
    Sawa T; Yoshida T; Ishiguro T; Ogawara M; Kawahara M; Yamamoto S; Yokota S; Maeda H; Asamoto H
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1745-9. PubMed ID: 14619509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
    Fujii T; Kunikane H; Okamoto H; Watanabe K; Kunitoh H; Mori K; Yokoyama A; Fukuda H; Tamura T; Saijo N
    Jpn J Clin Oncol; 2009 Dec; 39(12):784-90. PubMed ID: 19770129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent chemoradiotherapy in non-small cell lung cancer.
    Rowell NP; O'rourke NP
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002140. PubMed ID: 15495029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: results of a phase I-II study by the GOTHA group. Group d'Oncologie Thoracique des Régions Alpines.
    Alberto P; Mirimanoff RO; Mermillod B; Leyvraz S; Nagy-Mignotte H; Bolla M; Wellmann D; Moro D; Brambilla E
    Eur J Cancer; 1995; 31A(3):342-8. PubMed ID: 7786599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
    Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
    Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
    Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
    Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
    N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.
    Johnson DH; Turrisi AT; Chang AY; Blum R; Bonomi P; Ettinger D; Wagner H
    J Clin Oncol; 1993 May; 11(5):879-84. PubMed ID: 8387577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.